凯时对重症肺源性心脏病合并肺动脉高压患者的疗效

Efficacy of Lipo PGE1 on severe chronic pulmonary heart disease patients combined with pulmo- nary hypertension

目的评价凯时（Lipo PGE1）对重症肺源性心脏病合并肺动脉高压患者的疗效。方法将68例重症肺源性心脏病合并肺动脉高压患者，随机分为实验组和对照组各34例，实验组在常规抗感染、氧疗等治疗的基础上每日加用凯时10μg静脉微量泵入，对照组仅给予常规治疗。治疗前后检测血C型利钠肽（CNP）、肾上腺髓质素（ADM）水平及肺动脉压、动脉血氧分压（PaO2）、动脉血二氧化碳分压（PaCO2）。结果治疗后血CNP、ADM水平及肺动脉压、PaCO2较治疗前明显降低，PaO2较治疗前明显升高，两组比较差异有统计学意义（P〈0．05）。结论凯时治疗重症肺源性心脏病合并肺动脉高压能显著降低血CNP、ADM水平及肺动脉压，改善心功能及肺动脉高压，改善动脉血气。

Objective To evaluate the effects of Lipo PGE1 on severe chronic pulmonary heart disease patients combined with pulmonary hypertension. Methods Sixty-eight cases of severe chronic pulmonary heart disease combined with pulmonary hypertension were randomly divided into treatment group（34 cases） and control group（34 cases）. Both groups received the conventional antibiotics,oxygen therapy and other treatments, and 10 μg Lipo PGE1 were added to the treatment group every day. Serum CNP, ADM levels and pulmonary artery pressure, arterial oxygen tension （ PaO2 ） , partial pressure of ar- terial blood sputum dioxide （ PaCO2 ） were measured before and after the treatment. Results After treat- ment, blood CNP, ADM levels and pulmonary artery pressure, PaCO2 was significantly lower than those before treatment, PaO2 was significantly higher than that before treatment. There were significant differ- ence between the treatment group and the control group （P 〈 0.05）. Conclusions Lipo PGE1 can sig- nificantly reduce the serum CNP, ADM levels and pulmonary artery pressure of patients of chronic pulmo- nary heart disease combined with pulmonary hypertension, and improve the cardiac function, pulmonary hypertension and arterial blood gas.